Hospital
Ascension Calumet Hospital, INC
Ascension Calumet Hospital, INC was paid $3.78M by Medicaid between Jan 2018 and Dec 2024, across 85 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoASCENSION CALUMET HOSPITAL, INC
CHILTON, WI 53014
CHILTON, WI 53014
33aNPI1376541748assigned 07/11/2005
33bProvider typeCritical Access Hospital
28Total paid$3.78M
24GClaims102,065
24DCodes billed85
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#27 of 48
Median peer was paid$4.30M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCCULLOUGH, MICHAEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,721 | $324K | |
| 2019 | 17,602 | $341K | |
| 2020 | 13,110 | $375K | |
| 2021 | 15,250 | $476K | |
| 2022 | 16,820 | $736K | |
| 2023 | 18,555 | $878K | |
| 2024incomplete | 9,007 | $651K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 6,591 | 4,917 | $1.04M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 4,792 | 3,353 | $598K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 11% | 11,669 | 7,363 | $418K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 2,894 | 1,770 | $416K |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.0% | 921 | 521 | $303K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.2% | 6,634 | 4,648 | $271K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 859 | 670 | $118K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.7% | 1,244 | 1,006 | $65K |
| 80053 | Comprehensive metabolic panel | 1.4% | 6,253 | 4,324 | $54K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,630 | 1,277 | $36K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 601 | 481 | $36K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 562 | 443 | $35K |
73 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 782 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,676 | $24K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 631 | $23K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 703 | $21K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,952 | $21K |
| 80061 | Lipid panel | <1% | 1,964 | $18K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,485 | $16K |
| 80306 | <1% | 1,480 | $16K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 93 | $15K |
| 87634 | <1% | 357 | $15K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 969 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 784 | $14K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,508 | $13K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 49 | $11K |
| 81001 | <1% | 3,536 | $11K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 207 | $10K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,541 | $9K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 678 | $9K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 516 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 577 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,434 | $8K |
| 87631 | <1% | 52 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 43 | $5K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 71 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 705 | $4K |
| 84484 | <1% | 778 | $4K | |
| 85027 | <1% | 1,233 | $4K | |
| 99001 | <1% | 739 | $4K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 43 | $4K |
| 85610 | <1% | 1,984 | $3K | |
| 90686 | <1% | 181 | $3K | |
| A0380 | Bls mileage (per mile) | <1% | 73 | $3K |
| 87081 | <1% | 359 | $3K | |
| 99152 | <1% | 108 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 873 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 128 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,424 | $2K |
| 76000 | <1% | 263 | $2K | |
| 83690 | <1% | 370 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 72 | $2K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 64 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 91 | $1K |
| 83735 | <1% | 384 | $1K | |
| 81025 | <1% | 209 | $1K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 69 | $1K |
| 99406 | <1% | 199 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 661 | $814.42 |
| 85007 | <1% | 362 | $761.07 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 35 | $739.00 |
| 86140 | <1% | 249 | $723.29 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 18 | $528.52 |
| 93793 | <1% | 1,095 | $468.88 | |
| 85379 | <1% | 79 | $374.44 | |
| 83605 | <1% | 56 | $316.67 | |
| 85730 | <1% | 47 | $171.94 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 155 | $155.47 |
| 87186 | <1% | 34 | $135.38 | |
| 82077 | <1% | 16 | $115.30 | |
| 82728 | <1% | 18 | $113.32 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 208 | $92.91 |
| 90674 | <1% | 21 | $73.64 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,009 | $65.39 |
| 87077 | <1% | 16 | $58.42 | |
| 82043 | <1% | 14 | $32.89 | |
| A0425 | Ground mileage, per statute mile | <1% | 405 | $31.65 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 471 | $26.39 |
| 82962 | <1% | 18 | $23.62 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 537 | $21.93 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 446 | $4.52 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 54 | $1.66 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 107 | $1.14 |
| A9270 | Non-covered item or service | 0% | 1,819 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCULLOUGH, MICHAEL (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.